Bayer raises 2026 profit forecast as its pharmaceutical division shows a recovery
FROM THE WIRE · FINANCE.YAHOO.COM
Bayer (XTRA:BAYN) raised its 2026 profit forecast as its pharmaceutical division shows a recovery. Management pointed to strong demand for cancer drug Nubeqa and kidney and heart treatment Kerendia as key drivers. The updated 2026 outlook reflects confidence in Bayer's medium…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishAn upward revision to profit guidance at a European pharma group is relevant for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Bayer raised its 2026 profit forecast.
- 02Management pointed to strong demand for Nubeqa and Kerendia.
- 03Management expressed confidence in medium-term pharma earnings contribution.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets